***
Merck’s Mixed Quarter: The Blockbuster Bridge and the Post-Keytruda Strategy
The pharmaceutical world is constantly focused on the next big breakthrough, but for a giant like Merck & Co. Inc., the focus in early 2026 is squarely on managing a powerhouse present while building a compelling future. Following the release of its fourth-quarter and full-year 2025 results, the consensus from Wall Street is a familiar mix of relief over today’s performance and mild anxiety over tomorrow’s forecast.
On the surface, the company delivered a solid beat, with fourth-quarter worldwide sales hitting $16.4 billion, exceeding analyst expectations. Likewise, adjusted earnings per share (EPS) of $2.04 also nudged past the consensus forecast. Merck’s crown jewel, the oncology blockbuster Keytruda, remains an unstoppable growth engine, racking up $8.37 billion in sales for the quarter and a staggering $31.7 billion for the full year 2025, representing robust 7% growth. This is the drug that has effectively funded the company’s push into new therapeutic areas.
However, the forward-looking guidance for 2026 painted a slightly more complicated picture. Merck set its full-year sales outlook between $65.5 billion and $67.0 billion, a range that came in just shy of what some analysts were hoping for. Expected non-GAAP EPS was also slightly subdued, due in part to the one-time charges associated with major new acquisitions.
The ‘Blockbuster Bridge’ Takes Shape
That slightly muted 2026 outlook is all part of a calculated strategy to confront the biggest challenge facing the company: the eventual loss of exclusivity for Keytruda, which has recently been extended to late 2029. Merck is executing a multi-pronged approach, sometimes referred to as the “40:30:30” strategy, to ensure new products can collectively bridge the revenue gap.
One key component is the development of a subcutaneous (under-the-skin) version of the drug, known as Keytruda QLEX. This new formulation, which was approved in late 2025 and allows for a quicker injection compared to a traditional 30-minute infusion, is crucial for retaining market share in the face of future generic competition.
The company is also aggressively bolstering its pipeline through major business development. In a flurry of activity, Merck completed over $19 billion in acquisitions for companies like Verona Pharma and Cidara Therapeutics. These deals bring promising new assets into the fold, including a recently approved COPD drug, Ohtuvayre, and a late-stage influenza prophylactic, MK-1406. New launches in other areas, such as the pulmonary arterial hypertension treatment WINREVAIR, also added a healthy $1.4 billion to the bottom line in 2025.
The Few Challenges That Remain
While the new growth drivers look promising, the company is still navigating some headwinds. Notably, its powerhouse HPV vaccine, Gardasil, saw sales drop by 39% in 2025 due to new competition in the Chinese market and other factors. This decline in a key franchise highlights the constant need for innovation to offset losses elsewhere.
For investors, the story is one of steady execution. Analyst firms generally maintain a “Buy” or “Hold” rating, with many raising their price targets, acknowledging the strength of the pipeline and the strategic moves to mitigate the looming patent risks. As one analyst put it, the company’s efforts are transforming the Keytruda “patent cliff” into a much more manageable “hill.” The success of its newest launches and late-stage pipeline, including the highly anticipated oral PCSK9 inhibitor Enlicitide, will ultimately determine if Merck can transition smoothly into its next era of growth.
***